<DOC>
	<DOCNO>NCT01552369</DOCNO>
	<brief_summary>This study two different approach prevention CMV disease liver transplant recipient . The primary purpose determine Preemptive therapy well Prophylaxis therapy prevention CMV disease CMV seronegative recipient receive CMV positive liver transplant . Patients meet study criterion provide informed consent randomize within 10 day transplant receive open label design , either antiviral prophylaxis valganciclovir 900 mg orally daily 100 day preemptive therapy ( weekly monitoring asymptomatic CMV viremia plasma PCR ) 100 day initiation oral valganciclovir 900mg orally twice daily onset CMV viremia continue plasma PCR negative two consecutive weekly PCR test .</brief_summary>
	<brief_title>Prophylaxis Versus Preemptive Therapy Prevention CMV Liver Transplant Recipients</brief_title>
	<detailed_description>Title : Prophylaxis versus Preemptive Therapy Prevention CMV High-Risk R-/D+ Liver Transplant Recipients [ 'CAPSIL ' Study ] Population : CMV seronegative recipient ( 18 year age old ) liver transplant CMV seropositive donor ( R-/D+ ) Phase : IV Number Clinical Sites : 5 Study Duration : 7 year Subject Participation Duration : Until closure study exceed 7 year enrollment . Description Agent Intervention : Oral Valganciclovir hydrochloride : 2- [ ( 2-amino-6-oxo-6,9-dihydro-3H-purin-9-yl ) methoxy ] -3-hydroxypropyl ( 2S ) -2-amino-3-methylbutanoate . Currently market Valcyte Â® . The primary objective compare prophylaxis versus preemptive therapy use valganciclovir prevention CMV disease R-/D+ liver transplant recipient Secondary objective : To assess two preventive strategy : - Clinical outcome ( major bacterial , fungal non-CMV viral infection , rejection , graft loss mortality ) - Hematologic toxicity ( assessment neutropenia receipt hematopoietic growth factor study day 1-107 ) Study Design : This prospective , randomize , multicenter trial preemptive therapy vs. prophylaxis prevention CMV disease R-D+ liver transplant patient . Patients meet study criterion provide informed consent randomize within 10 day transplant receive open label design , either antiviral prophylaxis valganciclovir 900 mg orally daily preemptive therapy ( weekly monitoring CMV viremia plasma PCR ) 100 day post- randomization initiation oral valganciclovir 900mg orally twice daily onset CMV viremia continue plasma PCR negative two consecutive weekly PCR test ) . Valganciclovir dosages adjust renal dysfunction . Study participant follow intervention period ( 100 day post randomization ) 12 month post-transplant CMV disease , toxicity , clinical outcome ( opportunistic infection , rejection , graft loss mortality ) . Estimated Time Complete Enrollment : Approximately 5.0 year</detailed_description>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<criteria>Greater 18 yr age Negative CMV serology recipient Positive CMV serology donor Liver transplant within 10 day Absolute neutrophil count &gt; 1000 Female subject childbearing potential must negative pregnancy test agree use effective contraception 3 month receipt valganciclovir Male subject , vasectomy , must agree practice barrier method contraception 3 month receipt valganciclovir Enrollment investigational drug trial Hypersensitivity acyclovir , ganciclovir valganciclovir Breast feeding mother HIV infection Multiple organ transplant retransplantation Life expectancy le 72 hour</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>liver transplantation</keyword>
	<keyword>CMV disease</keyword>
	<keyword>valgancyclovir</keyword>
	<keyword>prophylaxis</keyword>
	<keyword>preemptive therapy</keyword>
</DOC>